EMA to scour medical literature for potential safety concerns from popular drugs
This article was originally published in SRA
The European Medicines Agency is preparing to launch a new service under which it would monitor medical literature for reports of suspected adverse reactions from drugs containing certain active substances, and then submit the relevant case reports into the EudraVigilance system on behalf of drug companies.
You may also be interested in...
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.